Novogene(SH:688315) Shang Hai Zheng Quan Bao·2025-05-07 20:27Group 1 - The company held its 2024 annual general meeting on May 7, 2025, where it elected the fourth board of directors and the supervisory board, with a term of three years starting from the approval date [1][2] - The board consists of three non-independent directors and two independent directors, while the supervisory board includes two non-employee representative supervisors and one employee representative supervisor [1][4] - Li Ruiqiang was elected as the chairman of the fourth board of directors during the first meeting of the new board [3] Group 2 - The first meeting of the fourth supervisory board was held on May 7, 2025, where Li Xingyuan was elected as the chairman of the supervisory board [5][28] - The company appointed several senior management personnel, including two vice presidents and a financial director, during the first board meeting [6][7] - The company expressed gratitude to departing senior management personnel for their contributions during their tenure [8] Group 3 - The company announced changes in its core technical personnel, with Yu Yang and Li Yanping no longer recognized as core technical personnel due to a reassignment of responsibilities [16][18] - New core technical personnel, Zhou Tingting and Li Yixue, were recognized based on their qualifications and contributions to the company [22] - The company maintains a stable research and development team, with a total of 387 R&D personnel as of December 31, 2024, representing 17.57% of the total workforce [23][24] Group 4 - The company has established a complete R&D system and has a robust patent portfolio, ensuring that the adjustment of core technical personnel will not adversely affect its technological advantages or core competitiveness [24][25] - The company continues to prioritize R&D and has mechanisms in place for talent development and recruitment [25][26]